Sequencing a Multi-Country Submission

Part of Regulatory Affairs and the Jurisdiction Map: Submissions and the Critical Path.

About 5 minutes. Free, in your language, no account needed.

Why this matters

A global study does not start everywhere. It starts somewhere, and the order you submit in changes how long the whole program takes, sometimes by months.

The naive approach submits everywhere simultaneously, reasoning that parallel is faster than sequential. Sometimes it is. Frequently it is not, because submissions are not independent: some authorities want to see another authority's assessment, some questions arrive from one country that you would rather answer before another country sees your dossier, and your own team's capacity to respond to questions is finite.

Sequencing is a genuine strategic decision and one of the places regulatory affairs adds the most value.

The dependencies that drive the order

Reference assessments. Several authorities give weight to an assessment already conducted by a stringent regulator. Where that applies, submitting there first and elsewhere second can shorten the second review substantially. Submitting simultaneously forfeits the benefit.

Product availability. A country cannot start without investigational product, and product needs an import route, which sometimes needs the trial authorization first and sometimes needs its own license from a different body. A country authorized in week six that cannot receive product until week twenty was not on the critical path in the way the plan assumed.

Question contagion. A question asked in one country is often a question your dossier invites everywhere. Answering it once, then improving the dossier before the next submission, is cheaper than answering it eleven times. This argues for a deliberate first wave.

Your own capacity. A regulatory team that can handle three concurrent question rounds well will handle nine badly, and a partial answer costs more than a delayed one.

Ethics committee calendars. Where ethics review is local, committee meeting dates are fixed points you cannot move, and they frequently dominate everything else.

Waves, not a single date

The practical shape is usually three waves.

A first wave of a small number of countries chosen because they are fast, because their assessment is valued elsewhere, or because they hold most of the expected enrollment. This wave also serves as a test of the dossier, and it should be small enough that a serious question found here can be fixed before the second wave sees it.

A second wave, the bulk, submitted after the first wave's questions are known and the dossier has been improved.

A third wave of countries with long lead times, unusual requirements or dependencies that were identified early and started early precisely because they are slow. This wave is often submitted first in real time even though it completes last, which is the part that confuses planning conversations.

In practice

A sponsor needs 600 participants across fourteen countries and wants first participant in by March.

The regulatory lead builds the sequence backwards. Two countries have local ethics review with committees meeting every two months, so their submissions go first regardless of anything else, because their calendar is the only truly immovable object. One country requires a separate approval for sample export, identified at design stage, which is started immediately and in parallel.

Four countries make up 60 percent of the expected enrollment, and they form the first assessed wave. The remaining seven go in the second wave, two weeks behind, so that questions from the first wave can improve the dossier.

The result is not the earliest possible date for any individual country. It is the earliest date at which 600 participants can actually be recruited, which is the number the business cares about, and it is six weeks earlier than the simultaneous plan would have delivered.

Note the shape of the reasoning: the immovable calendar first, the long lead times second, the enrollment concentration third, and speed last.

What this looks like when it goes wrong

A sponsor submits to all fourteen countries in the same week.

In week five, questions arrive from six of them. Three of the six ask a version of the same question, which reveals a genuine weakness in how the dossier presents the non-clinical safety margin.

The regulatory team of four now has six concurrent question rounds, three of which require input from the same non-clinical scientist, who is available for one of them this month. Responses go out late and thin. Three countries ask follow-up questions. Two applications lapse for late response.

Had the same weakness been found in a four-country first wave, it would have been fixed once, before ten other authorities ever saw it. The simultaneous submission did not fail because it was fast. It failed because it removed the opportunity to learn anything before committing everywhere.

Key takeaways